



**Universitätsklinikum Essen**  
 Institut für Neuropathologie  
 Direktorin: Univ.-Prof. Dr. med. K. Keyvani

Sekretariat: (02 01) 723 3325  
 Fax: (02 01) 723 5927  
 Email: [neuropathologie@uk-essen.de](mailto:neuropathologie@uk-essen.de)

(ADRESSETTE)

Patientenname: \_\_\_\_\_

Geburtsdatum: \_\_\_\_\_

w     m

## Anforderungsschein Molekulare Diagnostik

Eingangs-Nummer (intern)	Patienten-Name/Vorname	Datum
Tumorzellgehalt (intern)	Anmerkungen	Arzt/Ärztin

### ERREGERNACHWEIS

- HPV
- HCV
- Mycobacterien complex

### VERSCHIEDENES

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> IGH (Klonalität) | <input type="checkbox"/> 1p/19q FISH                | <input type="checkbox"/> miRNA PTC                         |
| <input type="checkbox"/> TCR (Klonalität) | <input type="checkbox"/> MGMT Promotor Methylierung | <input type="checkbox"/> Microsatelliteninstabilität (MSI) |
|   |   | <input type="checkbox"/> Microsatellitenprofil             |

### NGSEQUENZIERUNG

- BRCA PANEL**  
BRCA1 (1-24), BRCA2 (1-27)
- HTS1 PANEL**  
APC (1-16), DICER1 (1-28), PRKAR1A (1-11), PTEN (1-9), TSHR (1-10), WRN (2-35)
- NPP1.0 PANEL**  
ACVR1 (6-8), BRAF (11,15), CDKN2A (1-3), CDKN2B (1,2), CDKN2C (2,3), CIC (5,6,10,11,14,17,19,20), CTNNB1 (3,4,7,8,9), DICER1 (6,10,11,22,23,25,26,27), EGFR (2,7,8,15,18-21), FGFR1 (3,4,7,13,14,15,17), FUBP1 (1-20), H3F3A (2,3,4), H3F3B (2,3,4), HIST1H3B (1), HIST1H3C (1), HIST2H3C (1), IDH1 (3-10), IDH2 (1-10), KBTBD4 (3), MET (2,3,6,8,11,14,19), NFKBIA (1-6), NOTCH1 (3,6,7,8,9,26,34), NRAS (2,3,4), PDGFRA (5,7,12,14,18), PIC3CA (2,3,5,10,16,21), PIK3R1 (10,11,13,14), PTEN (1-9), RB1 (1-26), STK11 (1-9), TERT-Promotor, TP53 (2-11)
- CCP3 PANEL**  
BRAF (11,15), EGFR (18-21), ERBB2 (2,3,12,17,20,26), FGFR1 (3-7,10,12-15,17), FGFR2 Tr-A (6,8,10,11,13-15), FGFR2 Tr-B (8,9,12,18), FGFR3 (3,6,7,9,10,12,14,16,18), HRAS (2-4), IDH1 (4), IDH2 (4), KIT (9,10,11,13,14,17,18), KRAS (2-4), MET (3,8,11,14,19), NRAS (2-4), PDGFRA (12,14,18), PIK3CA (3,5,8,10,16,21), RET (7,10,11,13-16), STK11 (1-9), TERT-Promotor, TP53 (2-11)
- MAPK0 PANEL**  
Gesamter codierender Bereich von BRAF, GNA11, GNAQ, KRAS, MAP2K1, MAP2K2, NRAS

## MAPK1 PANEL

AKT1, AKT2, ARID1A, ARID1B, ATM, BAP1, BCLAF1, BRAF (11,15), BRCA1, BRCA2, CRAF, EGFR (18,19,20,21), ERBB2 (5,6,15,20,23,29), GNA11, GNAQ, GNAS, IDH1 (4), IDH2 (4), KDM6A, KIT (9,10,11,13,17,18), KRAS (2,3,4), MAP2K1, MAP2K2, MAPK1, MAPK3, MDM2, MET (3,8,11,14,19), MLH1, MSH2, NF1, NRAS (2,3,4), PALB2, PBRM1, PDGFRa (12,14,18), PIK3CA (3,5,10,16,21), PTEN, RNF43, RPA1, SF3B1 (14,15,16), SMAD4, SMARCA2, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

## NNGML1 PANEL

ALK (22-25), BRAF (11,15), CTNNB1 (3), EGFR (18-21), ERBB2 (8,19,20), FGFR1 (4-7,10,12-15), FGFR2 (Transcript A:6-15,18; Transcript B: 8), FGFR3 (3,6,7,9,10,12,14,16,18), FGFR4 (3,6,9,12,13,15,16), IDH1 (4), IDH2 (4), KRAS (2-4), MAP2K1 (2,3), MET (14, 16-19), NRAS (2-4), PIK3CA (10,21), PTEN (1-8), ROS1 (34-41), TP53 (4-8)

## GENFUSIONSPRODUKT-NACHWEIS

### ARCTL PANEL

Auf Fusionen untersuchte Gene (*Exone in Klammern*):

ALK (2, 4, 6, 10, 16-23, Intron 19), AXL (18-20), BRAF (7-11), CCND1 (1-4), FGFR1 (2, 8-10, 17), FGFR2 (2, 5, 7, 8-10, 17), FGFR3 (3, 5, 8-10, 17, Intron 17), MET (2, 4-6, 13-17, 21), NRG1 (1-3, 6), NTRK1 (2, 4, 6, 8, 10-13), NTRK2 (5, 7, 9, 11-17), NTRK3 (4, 7, 10, 13-16), PPARG (1-3, 5), RAF1 (4-7, 9-12), RET (2, 4, 6, 8-14), ROS1 (2, 4, 7, 31-37), THADA (24-30, 36, 37)

### ARSAR 2 PANEL

Auf Fusionen untersuchte Gene (*Exone in Klammern*):

ALK (19-22), BCOR (6-8,12,14,15), CAMTA1 (8-10), CCNB3 (2-6), CIC (19,20), EPC1 (9-11), EWSR1 (4-13), FOXO1 (1-3), FUS (4-11,14), GLI1 (4-7), HMGA2 (1-5), JAZF1 (2-4), MEAF6 (4,5), MKL2 (11-13), NCOA2 (11-14), NTRK1 (2, 4, 6, 8, 10-13), NTRK2 (5, 7, 9, 11-17), NTRK3 (4, 7, 10, 12-16), PAX3 (6-8), PDGFB (2,3), PLAG1 (1-4), ROS1 (2, 4, 7, 31-37), SS18 (4-6, 8-11), STAT6 (1-7, 16-19), TAF15 (5-7), TCF12 (4-6), TFE3 (3-6), TFG (4-7), USP6 (1-3), YWHAE (5)

## KIAA1549-BRAF-GENFUSIONSPRODUKT-NACHWEIS

## SEQUENZIERUNG SANGER

- |                |                     |                     |
|----------------|---------------------|---------------------|
| ■ ALK (20-25)  | ■ HFE (1,4)         | ■ PIK3CA (10,21)    |
| ■ BRAF (11,15) | ■ HIST1H3B (1)      | ■ PTEN (1-9)        |
| ■ CTNNB1 (3)   | ■ IDH1 (4)          | ■ RET (10,11,13-16) |
| ■ DDR2 (15-18) | ■ IDH2 (1)          | ■ TP53 (4-9)        |
| ■ EGFR (18-21) | ■ KIT (9,11,13,17)  | ■ TERT-Promotor     |
| ■ GNAS1 (7,8)  | ■ KRAS (2-4)        |                     |
| ■ H3F3A (2)    | ■ NRAS (2-4)        |                     |
| ■ H3F3B (2)    | ■ PDGFRa (12,14,18) |                     |

## IN SITU HYBRIDISIERUNG

- |                                   |                              |                              |
|-----------------------------------|------------------------------|------------------------------|
| ■ ALK Break Apart                 | ■ EGFR Amplifikation         | ■ NTRK1 Break Apart          |
| ■ BRAF Break Apart                | ■ EWS Break Apart            | ■ NTRK2 Break Apart          |
| ■ BCL2 Break Apart                | ■ FGFR1 Amplifikation        | ■ NTRK3 Break Apart          |
| ■ BCL6 Break Apart                | ■ FGFR2 Amplifikation        | ■ PHF1 Break Apart           |
| ■ BCR-ABL1 Fusion                 | ■ FOXO1 Break Apart          | ■ PIK3CA Amplifikation       |
| ■ CDKN2A/B Deletion/Amplifikation | ■ FUS Break Apart            | ■ RB1 Deletion/Amplifikation |
| ■ CIC Break Apart                 | ■ HER2 (ERBB2) Amplifikation | ■ RET Break Apart            |
| ■ MET Amplifikation               | ■ JAZF1 Break Apart          | ■ ROS1 Break Apart           |
| ■ COL1A1 Break Apart              | ■ MDM2 Amplifikation         | ■ SS18 (SYT) Break Apart     |
| ■ COL1A1/PDGFRb Fusion            | ■ MYC Amplifikation          | ■ TFE3 Break Apart           |
| ■ CFS1R Break Apart               | ■ MYC Break Apart            | ■ USP6 Break Apart           |
| ■ DDIT3 Break Apart               | ■ MYCN Amplifikation         | ■ VHL Deletion (LOH)         |
|                                   | ■ NR4A3 Break Apart          | ■ WWTR1 Break Apart          |
|                                   |                              | ■ YWHAE Break Apart          |

## 850K-METHYLIERUNGSANALYSE

ANDERE UNTERSUCHUNGEN: .....